DAREON-8: DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer (clinicaltrials.gov) - Sep 17, 2026 - P1 | N=46 | Active, not recruiting | Sponsor: Boehringer Ingelheim | Trial primary completion date: Sep 2026 ➔ Mar 2027
Trial primary completion date • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor
|